What is KPV peptide? A gut and skin tripeptide with no human studies

KPV is a three-amino-acid peptide that calms inflammation in lab dishes and in mice with chemically induced colitis. The evidence stops there. FDA’s May 2026 review found no human study of any kind, not a trial and not a case report, and a ClinicalTrials.gov search on November 2, 2026 found none registered. KPV is not FDA-approved. It is one of the unapproved peptides in our Peptides A-Z, and it has become popular online well ahead of its data.

What is KPV peptide?

KPV is three amino acids joined in a row: lysine (K), proline (P) and valine (V). It is the C-terminal (tail-end) sequence, positions 11 to 13, of alpha-melanocyte-stimulating hormone (alpha-MSH), a 13-amino-acid hormone made from the same precursor protein as ACTH. Alpha-MSH both darkens skin and dampens inflammation. KPV keeps some of the anti-inflammatory activity without the pigment effect.

FDA’s briefing document lists the free base as C16H30N4O4 with a molecular weight of 342.43 g/mol, and notes an acetate salt form (402.5 g/mol) that shares the same CAS number. “KPV” is a common name, not an official drug name, and FDA found multiple salts and derivatives sold under the same label. Some studies used related molecules, such as N-acetylated KPV or a KPV dimer, which are different substances. That matters for anyone reading a study and then a product label: they may not describe the same chemical.

What does KPV do?

In the lab, KPV lowers inflammatory signals, and the most consistent results are in the colon. How it does that is unsettled. KPV does not bind the main alpha-MSH receptors well in lab tests and does not raise cyclic AMP the way alpha-MSH does. A 2003 mouse study concluded it is unlikely to act through melanocortin receptors and more likely interferes with the inflammatory signal interleukin-1 beta. A 2008 study found that the gut transporter PepT1, which carries small peptides into cells and increases in inflamed colon, pulls KPV into intestinal and immune cells. FDA’s 2026 review summed it up: “the molecular targets underlying the pharmacological effects of KPV-related BDSs remain unknown.”

Read together, these studies show a consistent anti-inflammatory signal in rodents and in human cells grown in a dish. The nanoparticle and conjugate work is the most active thread, and it carries a warning for anyone comparing it with a plain capsule: the headline results came from engineered delivery systems, built because plain peptides break down in the gut and are poorly absorbed. None of it shows what KPV does in a person.

What is KPV used for?

Officially, nothing. Online, nearly everything. FDA’s review found websites promoting KPV for inflammatory bowel disease, psoriasis, wound healing, immune strength, nerve and stroke protection, tumors, mast cell activation syndrome, histamine intolerance, COVID-19 recovery, Lyme disease, mold toxicity and pain. The proposed compounded product FDA actually evaluated was narrower: a 0.1% cream or gel for “wound healing and inflammatory conditions.” The KPV benefits page sets each claim beside its strongest evidence, and most of the list has no KPV-specific research behind it.

Is KPV safe? What is known about side effects

Nobody can say, and that is the honest answer to the safety question. There is no list of side effects with percentages because no one has measured any in people. FDA’s May 12, 2026 evaluation lists the gaps:

• No human studies. “The nomination did not include, and FDA has not identified, any clinical studies or human exposure data for KPV via any route of administration.”
• No human pharmacokinetics. Nobody has measured how KPV is absorbed, distributed or cleared in people.
• No standard toxicology. FDA found no acute, repeat-dose, genotoxicity, reproductive or carcinogenicity studies.
• No adverse event reports. FDA’s searches of its FAERS database through December 3, 2025 and its food and supplement complaint system found no cases, which reflects the absence of documented use, not proven safety.
• Immunogenicity unknown. FDA said there is insufficient data to conclude KPV does not provoke immune reactions or form aggregates.
• Poor skin penetration. The only study in human tissue, using skin from cadavers, found KPV does not pass well through intact skin, which could limit a cream’s effect. Microneedles or a small electric current (iontophoresis) increased penetration.
• Unclear identity. Because “KPV” is not a standardized name, a vial labeled KPV may be the free base, the acetate, or something else.

Without pregnancy, drug-interaction or long-term data, there is no group for whom KPV has been shown to be safe. Anyone who is pregnant, breastfeeding, immunosuppressed or on treatment for bowel disease is working with no information at all, and that is worth raising with the clinician managing the condition.

Oral, topical or injected: what each route has behind it

Route is where the October 2026 policy draws its firmest line, and it does not line up neatly with the studies.

No route has an established human dose, and the KPV dosage page shows the animal figures and why they do not carry over. How long KPV takes to work is also unknown. The mouse colitis experiments ran for days to about a week, in an artificial disease, so they say nothing about a timeline for a person.

Is KPV legal? Its FDA status in detail

KPV has no new drug application, no FDA approval, no USP monograph and no authorization from the European Medicines Agency. The only process it has been through is the review of bulk substances that compounding pharmacies may use under section 503A.

What the October 2026 HHS policy changed

The office of the HHS Secretary, rather than FDA, issued this policy. As of November 2, 2026, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding KPV acetate in topical or oral dosage forms, when all ten conditions are met, until a final rule says whether KPV belongs on the 503A bulks list. Enforcement discretion is a choice not to enforce. It does not change what KPV is or what is known about it.

The conditions that matter most to a patient:

• The prescription must be valid and patient-specific.
• The product may contain one active ingredient only, so a blend with KPV in it falls outside the policy. That includes the KLOW blend, even though BPC-157 and TB-500 are also on the HHS list.
• The bulk powder must come from an FDA-registered manufacturer that follows good manufacturing practice, with a valid certificate of analysis. Our guide to reading a certificate of analysis explains what those tests cover.
• An oral product requires documentation that the specific formulation reaches adequate oral bioavailability in humans. FDA’s review found no human absorption data for KPV, so it is unclear what could meet this today.
• The label must read “This is a compounded drug product. Not for resale.”
• The compounder must report serious adverse events and quality problems to FDA’s MedWatch program and to the states involved.

What the policy leaves untouched:

• KPV is still not FDA-approved and still not on the 503A bulks list. No rule has been proposed.
• FDA has not reviewed any compounded KPV product for safety, effectiveness or quality. Injected KPV and KPV free base are outside the policy.
• The notice calls the policy a draft in places and says it “does not establish any rights for any person and is not binding on HHS or the public.” Written comments are open until November 13, 2026.
• HHS may revisit the policy if a safety signal or quality problem appears. It covers 503A compounding only, not outsourcing facilities, and states can be stricter.

HHS justified including KPV partly on the view that FDA’s safety conclusion “reflects an absence of information rather than an observed signal.” That is an accurate description of the data, and also the problem: no reported harm from a substance nobody has studied in people is a long way from evidence of safety. The evidence has not changed, which is why this page still says animal studies only. A 2019 review by Markus Böhm and Thomas Luger, dermatologists at the University of Münster, called KPV and related peptides promising candidates for treating skin wounds, and FDA’s review notes that researchers have said clinical studies are needed. Those studies still have not been done.

What research use only means

Vials labeled “for research use only” remain not legal to use on people, and the HHS policy gives them nothing; HHS says it is meant to discourage their use. Under 21 CFR 312.160, that label allows shipment solely for tests in laboratory animals or in test tubes, and it must read “Not for use in humans.” FDA’s 2026 review found websites promoting KPV as injections, oral capsules, topical products and nasal sprays, and in multi-peptide blends. None of these products has FDA-verified identity, purity, sterility or dose.

How KPV compares with BPC-157

BPC-157 is the peptide KPV is most often sold beside, and both are promoted for the gut. They are different molecules: KPV has 3 amino acids and BPC-157 has 15. Both are on the HHS list, with different limits. BPC-157 acetate is covered for subcutaneous, intramuscular, oral and topical use, while KPV acetate is covered for topical and oral use only. HHS cites human studies of BPC-157 in its justification; for KPV there are none to cite. Combining them in one product puts it outside the policy.

Access, cost and what to ask instead

KPV has no approved product, so no list price and no insurance route to compare. Compounded drugs generally fall outside standard pharmacy benefits, so anyone prescribed one would likely pay out of pocket.

Many people searching for KPV have a real problem, such as ulcerative colitis, Crohn’s disease or a stubborn skin condition. Crohn’s and ulcerative colitis both have approved treatments, tested in the human trials KPV lacks. If KPV has come up in a clinic or a forum, these are fair questions for a prescriber:

• What human evidence supports this for my condition, and what would you expect to see, by when?
• Is this one active ingredient, and is it in a form the HHS policy covers?
• Who made the bulk powder, and can I see the certificate of analysis?
• How does this interact with what I already take, given that no one has studied it?
• Which approved option would I be delaying, and what happens if my condition flares meanwhile?